Eurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2025)
Authors:
- M. V. EzhovM. V. Ezhov
- V. V. KukharchukVKV. V. Kukharchuk
- T. V. BalakhonovaTBT. V. Balakhonova
- V. S. GurevichVGV. S. Gurevich
- I. V. SergienkoISI. V. Sergienko
- A. A. SokolovASA. A. Sokolov
- A. A. SemenkinASA. A. Semenkin
- I. I. ShaposhnikISI. I. Shaposhnik
- N. M. AkhmedzhanovNAN. M. Akhmedzhanov
- O. L. BarbarashOBO. L. Barbarash
- M. G. BubnovaMBM. G. Bubnova
- M. I. VoevodaM. I. Voevoda
Open Access
- 2 June 2025
- journal article
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 2,p. 6-34
Abstract
Cardiovascular diseases are one of the main causes of mortality and disability among the population of the member countries of the Eurasian Association of Cardiology, which is directly related to the high prevalence of risk factors for atherosclerosis, among which dyslipidemia plays a leading role. The previous version of the Eurasian Recommendations for the Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis was presented in 2020. Over the past 5 years, approaches to risk stratification, diagnosis of subclinical atherosclerosis, and correction of dyslipidemia using various classes of lipid-lowering drugs have changed significantly. Among the initial updates, proposals should be highlighted for determining the blood lipid level in each adult or upon reaching the age of 18, using the SCORE and/or SCORE2 scales to stratify cardiovascular risk, and non-invasive imaging techniques to assess subclinical atherosclerosis. In the sections devoted to therapy, fixed combinations of lipid-lowering drugs, inclisiran, and bempedoic acid are presented. The section on the prevalence, significance and approaches to correction of hypertriglyceridemia, as well as the section on extracorporeal hemocorrection, has been expanded. A chapter on lipoprotein(a) is introduced. Sections on correction of dyslipidemia in cerebrovascular diseases, heart transplantation and HIV infection are presented. These recommendations will be useful to the phisicians of all specialties for the effective management of their patients.Keywords
This publication has 154 references indexed in Scilit:
- Alirocumab in Pediatric Patients With Heterozygous Familial HypercholesterolemiaJAMA Pediatrics, 2024
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special IssueJournal of Clinical Apheresis, 2023
- Statin Use for the Primary Prevention of Cardiovascular Disease in AdultsJAMA, 2022
- Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke PreventionJAMA Neurology, 2022
- Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelinesClinical Research in Cardiology Supplements, 2017
- Primary Prevention of Cardiovascular Disease with Statins in the ElderlyCurrent Atherosclerosis Reports, 2014
- Major Lipids, Apolipoproteins, and Risk of Vascular DiseaseJAMA, 2009
- Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemiaLiver Transplantation, 2009
- Long‐term plasma exchange for severe refractory hypertriglyceridemia: A decade of experience demonstrates safety and efficacyJournal of Clinical Apheresis, 2009
- Use of Fibrates in the Management of Hyperlipidemia in HIV-Infected Patients Receiving HAARTInfection, 2002